Cargando…
Future trends in incidence and long-term survival of metastatic cancer in the United States
BACKGROUND: Previous studies have demonstrated epidemiological trends in individual metastatic cancer subtypes; however, research forecasting long-term incidence trends and projected survivorship of metastatic cancers is lacking. We assess the burden of metastatic cancer to 2040 by (1) characterizin...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224927/ https://www.ncbi.nlm.nih.gov/pubmed/37244961 http://dx.doi.org/10.1038/s43856-023-00304-x |
_version_ | 1785050296533123072 |
---|---|
author | Hudock, Nicholas L. Mani, Kyle Khunsriraksakul, Chachrit Walter, Vonn Nekhlyudov, Larissa Wang, Ming Lehrer, Eric J. Hudock, Maria R. Liu, Dajiang J. Spratt, Daniel E. Zaorsky, Nicholas G. |
author_facet | Hudock, Nicholas L. Mani, Kyle Khunsriraksakul, Chachrit Walter, Vonn Nekhlyudov, Larissa Wang, Ming Lehrer, Eric J. Hudock, Maria R. Liu, Dajiang J. Spratt, Daniel E. Zaorsky, Nicholas G. |
author_sort | Hudock, Nicholas L. |
collection | PubMed |
description | BACKGROUND: Previous studies have demonstrated epidemiological trends in individual metastatic cancer subtypes; however, research forecasting long-term incidence trends and projected survivorship of metastatic cancers is lacking. We assess the burden of metastatic cancer to 2040 by (1) characterizing past, current, and forecasted incidence trends, and (2) estimating odds of long-term (5-year) survivorship. METHODS: This retrospective, serial cross-sectional, population-based study used registry data from the Surveillance, Epidemiology, and End Results (SEER 9) database. Average annual percentage change (AAPC) was calculated to describe cancer incidence trends from 1988 to 2018. Autoregressive integrating moving average (ARIMA) models were used to forecast the distribution of primary metastatic cancer and metastatic cancer to specific sites from 2019 to 2040 and JoinPoint models were fitted to estimate mean projected annual percentage change (APC). RESULTS: The average annual percent change (AAPC) in incidence of metastatic cancer decreased by 0.80 per 100,000 individuals (1988–2018) and we forecast an APC decrease by 0.70 per 100,000 individuals (2018–2040). Analyses predict a decrease in metastases to liver (APC = −3.40, 95% CI [−3.50, −3.30]), lung (APC (2019–2030) = −1.90, 95% CI [−2.90, −1.00]); (2030–2040) = −3.70, 95% CI [−4.60, −2.80]), bone (APC = −4.00, 95% CI [−4.30, −3.70]), and brain (APC = −2.30, 95% CI [−2.60, −2.00]). By 2040, patients with metastatic cancer are predicted to have 46.7% greater odds of long-term survivorship, driven by increasing plurality of patients with more indolent forms of metastatic disease. CONCLUSIONS: By 2040, the distribution of metastatic cancer patients is predicted to shift in predominance from invariably fatal to indolent cancers subtypes. Continued research on metastatic cancers is important to guide health policy and clinical intervention efforts, and direct allocations of healthcare resources. |
format | Online Article Text |
id | pubmed-10224927 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-102249272023-05-29 Future trends in incidence and long-term survival of metastatic cancer in the United States Hudock, Nicholas L. Mani, Kyle Khunsriraksakul, Chachrit Walter, Vonn Nekhlyudov, Larissa Wang, Ming Lehrer, Eric J. Hudock, Maria R. Liu, Dajiang J. Spratt, Daniel E. Zaorsky, Nicholas G. Commun Med (Lond) Article BACKGROUND: Previous studies have demonstrated epidemiological trends in individual metastatic cancer subtypes; however, research forecasting long-term incidence trends and projected survivorship of metastatic cancers is lacking. We assess the burden of metastatic cancer to 2040 by (1) characterizing past, current, and forecasted incidence trends, and (2) estimating odds of long-term (5-year) survivorship. METHODS: This retrospective, serial cross-sectional, population-based study used registry data from the Surveillance, Epidemiology, and End Results (SEER 9) database. Average annual percentage change (AAPC) was calculated to describe cancer incidence trends from 1988 to 2018. Autoregressive integrating moving average (ARIMA) models were used to forecast the distribution of primary metastatic cancer and metastatic cancer to specific sites from 2019 to 2040 and JoinPoint models were fitted to estimate mean projected annual percentage change (APC). RESULTS: The average annual percent change (AAPC) in incidence of metastatic cancer decreased by 0.80 per 100,000 individuals (1988–2018) and we forecast an APC decrease by 0.70 per 100,000 individuals (2018–2040). Analyses predict a decrease in metastases to liver (APC = −3.40, 95% CI [−3.50, −3.30]), lung (APC (2019–2030) = −1.90, 95% CI [−2.90, −1.00]); (2030–2040) = −3.70, 95% CI [−4.60, −2.80]), bone (APC = −4.00, 95% CI [−4.30, −3.70]), and brain (APC = −2.30, 95% CI [−2.60, −2.00]). By 2040, patients with metastatic cancer are predicted to have 46.7% greater odds of long-term survivorship, driven by increasing plurality of patients with more indolent forms of metastatic disease. CONCLUSIONS: By 2040, the distribution of metastatic cancer patients is predicted to shift in predominance from invariably fatal to indolent cancers subtypes. Continued research on metastatic cancers is important to guide health policy and clinical intervention efforts, and direct allocations of healthcare resources. Nature Publishing Group UK 2023-05-27 /pmc/articles/PMC10224927/ /pubmed/37244961 http://dx.doi.org/10.1038/s43856-023-00304-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Hudock, Nicholas L. Mani, Kyle Khunsriraksakul, Chachrit Walter, Vonn Nekhlyudov, Larissa Wang, Ming Lehrer, Eric J. Hudock, Maria R. Liu, Dajiang J. Spratt, Daniel E. Zaorsky, Nicholas G. Future trends in incidence and long-term survival of metastatic cancer in the United States |
title | Future trends in incidence and long-term survival of metastatic cancer in the United States |
title_full | Future trends in incidence and long-term survival of metastatic cancer in the United States |
title_fullStr | Future trends in incidence and long-term survival of metastatic cancer in the United States |
title_full_unstemmed | Future trends in incidence and long-term survival of metastatic cancer in the United States |
title_short | Future trends in incidence and long-term survival of metastatic cancer in the United States |
title_sort | future trends in incidence and long-term survival of metastatic cancer in the united states |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224927/ https://www.ncbi.nlm.nih.gov/pubmed/37244961 http://dx.doi.org/10.1038/s43856-023-00304-x |
work_keys_str_mv | AT hudocknicholasl futuretrendsinincidenceandlongtermsurvivalofmetastaticcancerintheunitedstates AT manikyle futuretrendsinincidenceandlongtermsurvivalofmetastaticcancerintheunitedstates AT khunsriraksakulchachrit futuretrendsinincidenceandlongtermsurvivalofmetastaticcancerintheunitedstates AT waltervonn futuretrendsinincidenceandlongtermsurvivalofmetastaticcancerintheunitedstates AT nekhlyudovlarissa futuretrendsinincidenceandlongtermsurvivalofmetastaticcancerintheunitedstates AT wangming futuretrendsinincidenceandlongtermsurvivalofmetastaticcancerintheunitedstates AT lehrerericj futuretrendsinincidenceandlongtermsurvivalofmetastaticcancerintheunitedstates AT hudockmariar futuretrendsinincidenceandlongtermsurvivalofmetastaticcancerintheunitedstates AT liudajiangj futuretrendsinincidenceandlongtermsurvivalofmetastaticcancerintheunitedstates AT sprattdaniele futuretrendsinincidenceandlongtermsurvivalofmetastaticcancerintheunitedstates AT zaorskynicholasg futuretrendsinincidenceandlongtermsurvivalofmetastaticcancerintheunitedstates |